ScreenerHero

IRWDIronwood Pharmaceuticals, Inc. Class A

NAS · US · Healthcare · Drug Manufacturers - Specialty & Generic · ironwoodpharma.com
4.290USD-1.61%Mkt Cap: 708.88M $P/E: 5.43

Ironwood Pharmaceuticals, Inc., a biotechnology company, focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and internationally. It sells linacl…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
MERCK Kommanditgesellschaft auf Aktien
$65.19BUSDP/E 23.7
TAK
Takeda Pharmaceutical Co. Ltd.
$58.06BUSD
HLN
Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
$43.98BUSDP/E 20.4
TEVA
Teva Pharmaceutical Industries Limited
$43.51BUSDP/E 62.2
ZOE
Zoetis Inc.
$29.89BUSDP/E 12.7
ZTS
Zoetis Inc.
$32.12BUSDP/E 12.7
UTHR
United Therapeutics Corporation
$22.01BUSDP/E 18.4
VTRS
Viatris, Inc.
$18.75BUSD
SOBI
Swedish Orphan Biovitrum AB
$15.34BUSDP/E 117.3
IPN
Ipsen S.A.
$14.67BUSDP/E 26.4
NBIX
Neurocrine Biosciences, Inc.
$15.51BUSDP/E 22.3
ELAN
Elanco Animal Health Incorporat
$11.98BUSD
RDY
Dr. Reddy's Laboratories Ltd
$10.15BUSDP/E 29.7
KRK
Krka, d. d.
$8.66BUSDP/E 19.0
ALKS
Alkermes plc
$8.11BUSDP/E 127.2
HIMS
Hims & Hers Health, Inc.
$7.88BUSD
LNTH
Lantheus Holdings Inc
$6.53BUSDP/E 23.9
AMRX
Amneal Pharmaceuticals, Inc. Class A
$6.24BUSDP/E 37.3
LQDA
Liquidia Corporation
$6.14BUSDP/E 49.0
KNSA
Kiniksa Pharmaceuticals, Ltd.
$6.08BUSDP/E 79.8

Key Statistics

Company
Market Cap708.88M $
Enterprise Value1.00B $
Revenue (TTM)389.32M $
Gross Profit300.62M $
Net Income (TTM)24.02M $
Revenue/Share2.387 USD
Last Price4.290 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINUS46333X1081
Valuation
P/E (Trailing)5.43
P/E (Forward)2.81
PEG—
EV/EBITDA4.21
EV/Revenue2.57
P/S1.76
P/B-3.14
EPS (TTM)0.75
EPS (Forward)1.47
52W Range
1.01069% of range5.780
52W High5.780 USD
52W Low1.010 USD
Profitability
Gross Margin77.22%
Oper. Margin70.16%
EBITDA Margin61.16%
Profit Margin8.11%
ROE-9.17%
ROA6.05%
Growth
Revenue Growth32.60%
Earnings Growth125.70%
Cash Flow & Leverage
Operating CF127.04M $
CapEx (TTM)34.00K $
FCF Margin31.29%
FCF Yield17.19%
Net Debt317.74M $
Net Debt/EBITDA1.33
Balance Sheet
Debt/Equity-2.28
Current Ratio6.06
Quick Ratio5.84
Book Value/Sh-1.3190 USD
Cash/Share0.4790 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1194:1000
Split DateApr 2, 2019
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.100 USD
Upside (mean)+42.2%
Target Range3.700 USD – 10.00 USD
$3.700+42.2% to mean$10.00
# Analysts4
Ownership
Shares Out.165.24M
Float136.77M
Insiders3.23%
Institutions98.43%
Short Interest
Short Ratio7.6d
Short % Float10.94%
Short % Out.10.01%
Shares Short16.54M
Short (prev mo.)16.23M
Technical
SMA 504.046 (+6.0%)
SMA 2003.841 (+11.7%)
Beta0.21
S&P 52W Chg18.16%
Avg Vol (30d)2.14M
Avg Vol (10d)1.88M
Technical Indicators
RSI (14)54.3
MACD0.0936
MACD Signal0.0787
MACD Hist.+0.0149
BB Upper4.645 USD
BB Middle4.113 USD
BB Lower3.581 USD
BB Width25.89%
ATR (14)0.2592 USD
Vol Ratio (20d)1.01x